Cohance Lifesciences Ltd Share Price (COHANCE)
Check the latest share price of Cohance Lifesciences Ltd, along with the price target, peer comparison, quarterly results, recent news, expert analysis, shareholding pattern, and other key fundamentals to make informed investment decisions.
as on 04:01PM, 16 Jun 2025
NSE
Cohance Lifesciences Ltd Stock Performance
Get live Cohance Lifesciences Ltd share price, day's high and low, historical returns, and market stats.
Day's Low
Day's High
₹980.6Day's Price Range₹1,013.852 Week's Low
52 Week's High
₹65652-Week Price Range₹1,360
| Returns % | |
| 1 Month Return | -6.92 % |
| 3 Month Return | -11.51 % |
| 1 Year Return | + 34.21 % |
| 3 Year Return | + 111.67 % |
| 5 Year Return | + 519.95 % |
| Market Stats | |
| Previous Close | ₹1,004.50 |
| Open | ₹1,004.50 |
| Volume | 1.26L |
| Upper Circuit | ₹1,205.40 |
| Lower Circuit | ₹803.60 |
Cohance Lifesciences Ltd Fundamentals & Key Indicators
Check Cohance Lifesciences Ltd market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
₹38,428.87 Cr
Return on Equity (ROE)
14.31
PE Ratio (TTM)
95.39
Return on capital employed (ROCE)
18.82
Industry PE ratio
57.39
Beta (LTM)
0.72
P/B Ratio
8.38
Dividend Yield
0PEG Ratio
-74.53
Quarterly Earnings Growth YOY
-27.43
EPS (TTM)
11.8
Sector
Pharmaceuticals
Book Value
80.56
Technical Analysis
Bearish
View Technical Analysis
How to invest in Cohance Lifesciences Ltd?
Investing in Cohance Lifesciences Ltd is simple. You can open a free INDstocks investment account on the INDmoney App. Search for Cohance Lifesciences Ltd or COHANCE on the app to check live prices of the stock and click on Buy or SIP. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.
For example: You can buy 10 shares of Cohance Lifesciences Ltd or start an SIP based on the market price on each investment date.
You can easily transfer money to your stock account via the INDmoney app and start investing in stocks like Cohance Lifesciences Ltd with just a few clicks!
Cohance Lifesciences Ltd Stock's Interest Amongst Investors
Cohance Lifesciences Ltd Valuation
Track how Cohance Lifesciences Ltd P/E has moved over time to understand its valuation trends.
Cohance Lifesciences Ltd in the last 5 years
Lowest (4.48x)
March 30, 2020
Industry (57.39x)
June 13, 2025
Today (95.39x)
June 13, 2025
Highest (139.56x)
November 5, 2024
Today’s Price to Earnings Ratio: 95.39x
Cohance Lifesciences Ltd Stock Recommendation
Get updated buy, sell, and hold recommendations by analysts on Cohance Lifesciences Ltd.
based on 6 analysts
100.00%
Buy
0.00%
Hold
0.00%
Sell
100% of analysts recommend a 'BUY' rating for Cohance Lifesciences Ltd. Average target price of ₹1313
Source: S&P Global Market Intelligence
Cohance Lifesciences Ltd Share Price Target
Get share price movements and forecasts by analysts on Cohance Lifesciences Ltd.
Cohance Lifesciences Ltd price forecast by 6 analysts
Upside of30.71%
High
₹1500
Target
₹1313.00
Low
₹1180
Cohance Lifesciences Ltd target price ₹1313, a slight upside of 30.71% compared to current price of ₹993.5. According to 6 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Cohance Lifesciences Ltd revenue growth forecast
Expected growth rate Q1, FY2027:285.69%
Forecast
Actual
Including amortisation and stock based compensations
Cohance Lifesciences Ltd EPS growth forecast
EPS estimate Q1, FY2027:101.53%
Forecast
Actual
Source: S&P Global Market Intelligence
Cohance Lifesciences Ltd Financial Results
Get the annual and quarterly financial summary of Cohance Lifesciences Ltd, including revenue, profit, loss and more.
Indices Featuring Cohance Lifesciences Ltd Stock
Check stock indices that include Cohance Lifesciences Ltd.
Cohance Lifesciences Ltd Earnings and Dividends
View detailed summary of the earnings and dividend history of Cohance Lifesciences Ltd.
Cohance Lifesciences Ltd Earnings Results
Cohance Lifesciences Ltd’s net profit fell -21.29% since last year same period to ₹42.01Cr in the Q4 2024-2025. On a quarterly growth basis, Cohance Lifesciences Ltd has generated -49.31% fall in its net profits since last 3-months.
Read More about Earnings ResultsCohance Lifesciences Ltd Dividends September,2022
In the quarter ending June 2022, Cohance Lifesciences Ltd has declared dividend of ₹1 - translating a dividend yield of 1.11%.
Read More about Dividends
Cohance Lifesciences Ltd Shareholding Pattern
View the shareholding pattern breakup of promoters, FIIs, DIIs, and retail investors in Cohance Lifesciences Ltd.
| Investors | Holdings % | Quarterly Trend | 3M change |
|---|---|---|---|
| Promoter Holdings | 66.41% | 32.56 | |
| Foreign Institutions | 7.38% | ||
| Mutual Funds | 8.65% | ||
| Retail Investors | 15.18% | ||
| Others | 2.38% |
Cohance Lifesciences Ltd vs Peers
Compare market cap, revenue, PE, and other key metrics of Cohance Lifesciences Ltd with its industry peers.
Company | Analyst View | Market Cap(in ₹ Cr) | 5 Year CAGR | Debt to Asset Ratio | Net Profit(in ₹ Cr) | Yearly Revenue(in ₹ Cr) |
|---|---|---|---|---|---|---|
| BUY | 38,428.87 | 103.99% | 0.52 | 300 | 1,051 | |
| BUY | 17,430.61 | 18.38% | 0.57 | 72 | 6,702 | |
| NA | 5,383.81 | 2.62% | 0.79 | -388 | 75 | |
| BUY | 14,436.59 | 43.15% | 0.67 | 244 | 1,515 | |
| HOLD | 22,503.43 | 134.96% | 0.55 | 258 | 1,375 |
Cohance Lifesciences Ltd News & Key Events
Latest news and events in one place to help you make informed investing decisions in Cohance Lifesciences Ltd.
Suven Pharmaceuticals Rebrands to Cohance Lifesciences - 08 May, 2025
Suven Pharmaceuticals has changed its name to Cohance Lifesciences, effective May 7, 2025. This rebranding reflects the company's commitment to innovation in the CDMO sector.Suven Pharmaceuticals Targets $1 Billion Revenue by 2030 - 05 May, 2025
Suven Pharmaceuticals reports increased engagement at industry events, focusing on advanced capabilities like ADCs and peptides. The company aims for $1 billion in revenue by 2030, driven by CDMO momentum.Suven Pharmaceuticals Merger with Cohance Approved - 25 Apr, 2025
The merger between Suven Pharmaceuticals and Cohance Lifesciences will take effect on May 1, 2025, aiming to create a diversified CDMO platform. The National Company Law Tribunal approved the merger on March 27, with plans for aggressive expansion and a revenue target of Rs 6000 crore by FY29.Suven Pharma Advances with Merger and Global Engagement - 23 Apr, 2025
Suven Pharmaceuticals received regulatory approval for increasing foreign investment post-merger with Cohance Lifesciences. The company also sees heightened interest from global pharma firms seeking alternatives to China.
Insights on Cohance Lifesciences Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTPromoter Holding Up
Promoters have increased holdings from 50.10% to 66.41% in May 2025 quarter
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 4 quarters, 248.85 Cr → 412.59 Cr (in ₹), with an average increase of 15.3% per quarter
NO EFFECTAgainst Peers
In the last 3 years, Torrent Pharmaceuticals Ltd has given 132.4% return, outperforming this stock by 20.7%
- NO EFFECT
Against Peers
In the last 1 year, Divis Laboratories Ltd has given 46.1% return, outperforming this stock by 11.9%
NEGATIVE IMPACTFII Holding Down
Foreign Institutions have decreased holdings from 11.05% to 7.38% in May 2025 quarter
- NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 2 quarters, 82.88 Cr → 42.01 Cr (in ₹), with an average decrease of 49.3% per quarter
- NEGATIVE IMPACT
Price Dip
In the last 3 months, COHANCE stock has moved down by -11.5%
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 22.23% to 15.18% in May 2025 quarter
- NEGATIVE IMPACT
MF Holding Down
Mutual Funds have decreased holdings from 13.04% to 8.65% in May 2025 quarter
About Cohance Lifesciences Ltd
Revenue: ₹402.02Cr as on March 2025 (Q4 FY25)
Net Profit: ₹38.73Cr as on March 2025 (Q4 FY25)
Listing date: 05 Mar, 2020
Chairperson Name: Annaswamy Vaidheesh
| Organisation | Cohance Lifesciences Ltd |
| Industry | Pharmaceuticals |
| CEO | Annaswamy Vaidheesh |
| E-voting on shares | Click here to vote |
Mutual Funds that own Cohance Lifesciences Ltd
Check out the Mutual Funds with significant holdings in Cohance Lifesciences Ltd.
FAQs
What is Cohance Lifesciences Ltd share price today?
Cohance Lifesciences Ltd share price today stands at ₹993.5, Open: ₹1004.5, Previous Close: ₹1004.5, High: ₹1013.8, Low: ₹980.6, 52 Week High: ₹1360, 52 Week Low: ₹656.
What is today's traded volume of Cohance Lifesciences Ltd?
Today's traded volume of Cohance Lifesciences Ltd is 1.26L. Which means that 1.26L shares of Cohance Lifesciences Ltd were bought and sold on the stock market during today's trading session.
What is Cohance Lifesciences Ltd's market cap today?
Today's market capitalisation of Cohance Lifesciences Ltd is ₹38,428.87 Cr. Market cap or market capitalisation is the total value of a company’s outstanding shares in the stock market, calculated by multiplying the current share price by the total number of shares issued by the company.
What is the 52 week high and 52 week low range of Cohance Lifesciences Ltd?
Cohance Lifesciences Ltd’s 52 week high is ₹1360 and 52 week low is ₹656. The current share price of Cohance Lifesciences Ltd is ₹993.5, which is -26.95% down from its 52 week high and 51.45% up from its 52 week low.